Akari Therapeutics (NASDAQ:AKTX) Issues Earnings Results, Misses Expectations By $686.67 EPS

Akari Therapeutics (NASDAQ:AKTX) issued its quarterly earnings results on Wednesday. The biopharmaceutical company reported ($688.00) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.33) by ($686.67), reports.

Akari Therapeutics Price Performance

AKTX stock traded up $13.13 during midday trading on Friday, reaching $18.27. The stock had a trading volume of 32,893,160 shares, compared to its average volume of 424,160. Akari Therapeutics has a twelve month low of $3.02 and a twelve month high of $56.80. The business has a fifty day simple moving average of $5.37 and a two-hundred day simple moving average of $10.53.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently issued reports on AKTX shares. Weiss Ratings reissued a “sell (e+)” rating on shares of Akari Therapeutics in a report on Monday, April 20th. Maxim Group lowered Akari Therapeutics from a “buy” rating to a “hold” rating in a research note on Wednesday, April 8th. Finally, HC Wainwright boosted their target price on shares of Akari Therapeutics to $27.00 and gave the company a “buy” rating in a research note on Wednesday, April 1st. Two investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of “Hold” and a consensus price target of $89.00.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in Akari Therapeutics stock. Armistice Capital LLC bought a new position in shares of Akari Therapeutics PLC (NASDAQ:AKTX) during the 4th quarter, according to its most recent 13F filing with the SEC. The firm bought 2,723,966 shares of the biopharmaceutical company’s stock, valued at approximately $787,000. Armistice Capital LLC owned 5.95% of Akari Therapeutics as of its most recent filing with the SEC. 5.06% of the stock is currently owned by institutional investors.

Key Akari Therapeutics News

Here are the key news stories impacting Akari Therapeutics this week:

• Positive Sentiment: Akari reported breakthrough preclinical data showing AKTX-101 worked synergistically with KRAS inhibition in pancreatic cancer models, boosting investor optimism about its lead ADC program. Article Title
• Positive Sentiment: Market commentary highlighted the stock’s surge after the cancer-data release, with some traders pointing to possible upside if the platform continues to show promise. Article Title
• Neutral Sentiment: Akari announced a $5.5 million private placement offering to fund development of AKTX-101, providing near-term cash but also signaling dilution risk. Article Title
• Neutral Sentiment: The company also announced an ADS ratio change and reverse split, a corporate action that can alter the share structure and often contributes to trading volatility. Article Title
• Negative Sentiment: Akari’s latest quarterly results missed expectations by a wide margin, underscoring that the company remains highly speculative and financially challenged. Article Title
• Negative Sentiment: Trading in AKTX was halted multiple times for LULD pauses, reflecting extreme intraday volatility as investors reacted to the news flow. Article Title

About Akari Therapeutics

Akari Therapeutics plc is a clinical-stage biopharmaceutical company focused on the discovery and development of novel complement inhibitors for the treatment of inflammatory and immunological diseases. The company’s research centers on modulation of the complement cascade, a key component of the innate immune system, with the goal of delivering targeted therapies to patients suffering from rare and severe disorders.

Akari’s lead pipeline asset is sutimlimab, a humanized monoclonal antibody that selectively inhibits the C1s protein and is being evaluated in pivotal clinical studies for cold agglutinin disease.